Puma Biotechnology Net Cash Flow 2010-2025 | PBYI

Puma Biotechnology net cash flow from 2010 to 2025. Net cash flow can be defined as the total change in cash for the company over the given period.

Puma Biotechnology Net Cash Flow 2010-2025 | PBYI

Puma Biotechnology net cash flow from 2010 to 2025. Net cash flow can be defined as the total change in cash for the company over the given period.
Related Stocks
Company NameMarket
Cap
AstraZeneca (AZN)$214.8B
Amgen (AMGN)$160.4B
Gilead Sciences (GILD)$135.3B
Vertex Pharmaceuticals (VRTX)$119B
Bristol Myers Squibb (BMY)$97.8B
CSL (CSLLY)$78.3B
GSK (GSK)$74.7B
Regeneron Pharmaceuticals (REGN)$59.4B
Alnylam Pharmaceuticals (ALNY)$42.3B
Argenex SE (ARGX)$35B
BioNTech SE (BNTX)$26.7B
Royalty Pharma (RPRX)$19.9B
Insmed (INSM)$19.8B
Biogen (BIIB)$18.9B
Illumina (ILMN)$15.5B
Genmab (GNMSF)$14.5B
Genmab (GMAB)$14.1B
Incyte (INCY)$13.3B
Moderna (MRNA)$12.5B
Exelixis (EXEL)$12.2B
BioMarin Pharmaceutical (BMRN)$11.2B
Ascendis Pharma (ASND)$10.8B
QIAGEN (QGEN)$10.7B
Swedish Orphan Biovitrum (BIOVF)$10.6B
Exact Sciences (EXAS)$9.8B
Verona Pharma American Depositary Share (VRNA)$8.9B
Bio-Techne Corp (TECH)$8.4B
Blueprint Medicines (BPMC)$8.3B
Roivant Sciences (ROIV)$7.9B
Legend Biotech (LEGN)$7.7B